secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0000950170-25-066945
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q1 net loss $40.5M ($0.41/sh); INFRONT-3 data on track for Q4 2025
--------------------------------------------------------------------------

- Net loss of $40.5M ($0.41/sh) vs $36.1M ($0.38/sh) in Q1 2024; collaboration revenue $3.7M (down from $15.9M).
- Cash, cash equivalents, and investments total $354.6M as of March 31, 2025; runway extended into second half of 2027.
- Topline INFRONT-3 Phase 3 data for latozinemab in FTD-GRN expected in Q4 2025; enrollment complete in PROGRESS-AD Phase 2 for AL101.
- Giacomo Salvadore appointed Chief Medical Officer; 2025 guidance reiterated: R&D $175-185M, G&A $55-65M, collab rev $5-15M.
- Advancing preclinical Alector Brain Carrier programs including anti-amyloid beta antibody and GCase enzyme replacement therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017025066945/0000950170-25-066945-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017025066945/alec-20250508.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-066945

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer